docruДоктор.РуTitle1727-23782713-2994ООО "ГК "РУСМЕДИКАЛ"10.31550/1727-2378-2024-23-4-20-26docru-113Research ArticleОБЗОРЫREVIEWSОментин-1 и ишемическая болезнь сердцаOmentin-1 and Coronary Heart Diseasehttps://orcid.org/0000-0003-2889-0706КолодинаД. А.KolodinaD. A.

Колодина Диана Александровна — ассистент кафедры терапии факультетской с курсом эндокринологии, кардиологии с клиникой им. акад. Г.Ф. Ланга

197022, г. Санкт-Петербург, ул. Льва Толстого, д. 6-8

Kolodina, D.A.

6-8 Lev Tolstoy Str., St. Petersburg, 197022

diana.kolodina@gmail.comhttps://orcid.org/0000-0002-9541-0947ДрагановаА. С.DraganovaA. S.

Драганова Анна Сергеевна — к. м. н., врач-кардиолог консультативно-диагностического центра

197341, г. Санкт-Петербург, ул. Аккуратова, д. 2

 

Draganova, A.S.

2 Akkuratova Str., St. Petersburg, 197341

anna.s.draganova@gmail.comhttps://orcid.org/0000-0002-5349-2227БеляеваО. Д.BelyaevaO. D.

Беляева Ольга Дмитриевна — д. м. н., доцент, профессор кафедры терапии факультетской с курсом эндокринологии, кардиологии с клиникой им. акад. Г.Ф. Ланга

197022, г. Санкт-Петербург, ул. Льва Толстого, д. 6-8

Belyaeva, O.D.

6-8 Lev Tolstoy Str., St. Petersburg, 197022

olgad.bel@gmail.comhttps://orcid.org/0000-0002-5358-5968БерковичО. А.BerkovichO. A.

Беркович Ольга Александровна — д. м. н., профессор, профессор кафедры терапии факультетской с курсом эндокринологии, кардиологии с клиникой им. акад. Г.Ф. Ланга

197022, г. Санкт-Петербург, ул. Льва Толстого, д. 6-8

Berkovich, O.A.

6-8 Lev Tolstoy Str., St. Petersburg, 197022

oberkovich@mail.ruФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова» Минздрава РоссииРоссияI.P. Pavlov First St. Petersburg State Medical UniversityRussian FederationФГБУ «Национальный медицинский исследовательский центр имени В.А. Алмазова» Минздрава РоссииРоссияV.A. Almazov National Medical Research CenterRussian Federation2024160220252342026Copyright © Колодина Д.А., Драганова А.С., Беляева О.Д., Беркович О.А., 20252025Колодина Д.А., Драганова А.С., Беляева О.Д., Беркович О.А.Kolodina D.A., Draganova A.S., Belyaeva O.D., Berkovich O.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://docru.elpub.ru/jour/article/view/113Цель

Цель. Обобщить результаты исследований связи уровня оментина-1 и ишемической болезни сердца.

Основные положения

Основные положения. Жировая ткань в настоящее время рассматривается как эндокринный орган, синтезирующий биологически активные факторы, известные как адипоцитокины, которые могут принимать участие в патогенезе связанных с ожирением метаболических и сердечно-сосудистых заболеваний, в частности, ишемической болезни сердца. Оментин-1 — адипоцитокин, который преимущественно секретируется висцеральной жировой тканью и играет важную роль в развитии хронических воспалительных заболеваний, включая ишемическую болезнь сердца. Известны две изоформы оментина: оментин-1 и оментин-2. Оментин-1 является основной циркулирующей формой оментина. Его уровень в крови здоровых людей, по данным разных авторов, варьирует от 1,61 до 815,3 нг/мл. В ряде исследований было установлено, что концентрация оментина-1 в крови у женщин выше, чем у мужчин, что может быть обусловлено половым диморфизмом жировой ткани. Результаты исследований свидетельствуют о том, что уровни циркулирующего в крови оментина-1 связаны с различными метаболическими факторами риска. В обзоре описаны основные молекулярные механизмы, определяющие данные эффекты оментина-1. Снижение уровня оментина-1 в сыворотке крови может рассматриваться как независимый предиктор ишемической болезни сердца и коррелирует с тяжестью и прогнозом этого заболевания. В ряде работ установлена ассоциация между носительством различных вариантов гена оментина-1 (ITLN1), ишемической болезнью сердца и ожирением. В статье проведен анализ имеющихся данных, касающихся роли при ишемической болезни сердца уровня оментина-1, определяемого не только в крови, но и в подкожной и висцеральной жировой ткани. Проанализированы возможные перспективы применения различных молекул, способных увеличивать уровень оментина-1 в крови.

Заключение

Заключение. Снижение уровня оментина-1 может являться независимым предиктором ишемической болезни сердца и связано с тяжестью и прогрессированием заболевания. Вероятно, оментин-1 может выступать в качестве альтернативного диагностического инструмента для обеспечения оптимального ведения пациентов с ишемической болезнью сердца. Исследования влияния оментина-1 на прогноз у больных с различными формами ишемической болезни сердца во многом неоднозначны и поэтому необходимы дальнейшие, более комплексные исследования.

Aim

Aim. The purpose of the review is to summarize the results of studies on the relationship between the level of omentin-1 and coronary artery disease (CAD).

Key points

Key points. Adipose tissue is currently considered as an endocrine organ synthesizing biologically active factors known as adipocytokines, which may be involved in the pathogenesis of obesity-related metabolic and cardiovascular diseases, in particular, CAD. Omentin-1 is an adipocytokine that is predominantly secreted by visceral adipose tissue and plays an important role in the development of chronic inflammatory diseases, including CAD. Two isoforms of omentin are known: omentin-1 and omentin-2. Omentin-1 is the main circulating form of omentin. Its blood level in healthy people, according to different authors, varies from 1.61 to 815.3 ng/ml. A number of studies have found that the concentration of omentin-1 in the blood of women is higher than that of men, which may be due to sexual dimorphism of adipose tissue. The results of the studies indicate that the levels of omentin-1 circulating in the blood are associated with various metabolic risk factors. The review describes the main molecular mechanisms that determine these effects of omentin-1. A decrease in serum omentin-1 levels can be considered as an independent predictor of CAD and correlates with the severity and prognosis of this disease. A number of studies have established an association between the carriage of various variants of the omentin-1 (ITLN1) gene, CAD and obesity. The article analyzes the available data on the role of the level of omentin-1 in CAD, determined not only in the blood, but also in subcutaneous and visceral adipose tissue. The possible prospects for the use of various molecules capable of increasing the level of omentin-1 in the blood are analyzed.

Conclusion

Conclusion. A decrease in the level of omentin-1 may be an independent predictor of CAD and is associated with the severity and progression of the disease. It is likely that omentin-1 can act as an alternative diagnostic tool to ensure optimal management of patients with CAD. Studies of the effect of omentin-1 on the prognosis in patients with various forms of CAD are largely ambiguous and therefore further, more comprehensive studies are needed.

ишемическая болезнь сердцаострый коронарный синдромоментин-1адипокиныподкожная и висцеральная жировая тканьген оментина-1 (ITLN1)coronary artery diseaseacute coronary syndromeomentin-1adipokinessubcutaneous and visceral adipose tissueomentin-1 gene (ITLN1)ReferencesБойцов С.А., Драпкина О.М., Шляхто Е.В. и др. Исследование ЭССЕ-РФ (Эпидемиология сердечно-сосудистых заболеваний и их факторов риска в регионах Российской Федерации). Десять лет спустя. Кардиоваскулярная терапия и профилактика. 2021; 20(5):3007. DOI: 10.15829/1728-8800-2021-3007Boytsov S.A., Drapkina O.M., Shlyakhto E.V. et al. Epidemiology of Cardiovascular Diseases and their Risk Factors in Regions of Russian Federation (ESSE-RF) study. Ten years later. Cardiovascular Therapy and Prevention. 2021;20(5):3007. (in Russian). DOI: 10.15829/1728-8800-2021-3007Komajda M., Cosentino F., Ferrari R. et al. CICD Investigators Group. The ESC-EORP Chronic Ischaemic Cardiovascular Disease Long Term (CICD LT) registry. Eur. Heart J. Qual. Care Clin. Outcomes. 2021;7(1):28–33. DOI: 10.1093/ehjqcco/qcz057Komajda M., Cosentino F., Ferrari R. et al. CICD Investigators Group. The ESC-EORP Chronic Ischaemic Cardiovascular Disease Long Term (CICD LT) registry. Eur. Heart J. Qual. Care Clin. Outcomes. 2021;7(1):28–33. DOI: 10.1093/ehjqcco/qcz057Концевая А.В., Шальнова С.А., Драпкина О.М. Исследование ЭССЕ-РФ: эпидемиология и укрепление общественного здоровья. Кардиоваскулярная терапия и профилактика. 2021;20(5):2987. DOI: 10.15829/1728-88002021-2987Kontsevaya A.V., Shalnova S.A., Drapkina O.M. ESSE-RF study: epidemiology and public health promotion. Cardiovascular Therapy and Prevention. 2021;20(5):2987. (in Russian). DOI: 10.15829/1728-88002021-2987Миклишанская С.В., Мазур Н.А. Типы ожирения и их влияние на отдаленные исходы у больных с сердечно-сосудистыми заболеваниями. Ожирение и метаболизм. 2021;18(2):125–131. DOI: 10.14341/omet12367Miklishanskaya S.V., Mazur N.A. Types of obesity and their impact on long-term outcomes in patients with cardiovascular disease. Obesity and metabolism. 2021;18(2):125–131. (in Russian). DOI: 10.14341/omet12367Чумакова Г.А., Покутнев А.П., Веселовская Н.Г. Особенности инфаркта миокарда у больных с ожирением. Российский кардиологический журнал. 2017;(4):75–80. DOI: 10.15829/1560-4071-2017-4-75-80Chumakova G.A., Pokutnev A.P., Veselovskaya N.G. Specifics of myocardial infarction in obesity. Russian Journal of Cardiology. 2017;(4):75–80. (in Russian). DOI: 10.15829/1560-4071-2017-4-75-80Драганова А.С., Полякова Е.А., Колодина Д.А. и др. Концентрация оментина-1 в сыворотке крови у больных ишемической болезнью сердца. Трансляционная медицина. 2019;6(6):5–13. DOI: 10.18705/2311-44952019-6-6-5-13Draganova A.S., Polyakova E.A., Kolodina D.A. et al. Concentration omentin-1 in the serum of patients with coronary heart disease. Translational Medicine. 2019;6(6):5–13. (in Russian). DOI: 10.18705/2311-44952019-6-6-5-13Осипова Е.С., Веселовская Н.Г., Чумакова Г.А., Елыкомов В.А. Факторы риска рестеноза коронарных артерий после стентирования у женщин с ожирением в период менопаузы. Российский кардиологический журнал. 2018;(5):34–39. DOI: 10.15829/1560-4071-2018-5-34-39Osipova E.S., Veselovskaya N.G., Chumakova G.A., Elykomov V.A. Risk factors of coronary arteries restenosis after stenting in postmenopausal women with obesity. Russian Journal of Cardiology. 2018;(5): 34–39. (in Russian). DOI: 10.15829/1560-4071-2018-5-34-39Tanaka K., Fukuda D., Sata M. Roles of epicardial adipose tissue in the pathogenesis of coronary atherosclerosis — an update on recent findings. Circ. J. 2020;85(1):2–8. DOI: 10.1253/circj.CJ-20-0935Tanaka K., Fukuda D., Sata M. Roles of epicardial adipose tissue in the pathogenesis of coronary atherosclerosis — an update on recent findings. Circ. J. 2020;85(1):2–8. DOI: 10.1253/circj.CJ-20-0935Liu Z., Wang S., Wang Y. et al. Association of epicardial adipose tissue attenuation with coronary atherosclerosis in patients with a high risk of coronary artery disease. Atherosclerosis. 2019;284: 230–236. DOI: 10.1016/j.atherosclerosis.2019.01.033Liu Z., Wang S., Wang Y. et al. Association of epicardial adipose tissue attenuation with coronary atherosclerosis in patients with a high risk of coronary artery disease. Atherosclerosis. 2019;284: 230–236. DOI: 10.1016/j.atherosclerosis.2019.01.033Clemente-Suárez V.J., Redondo-Flórez L., Beltrán-Velasco A.I. et al. The role of adipokines in health and disease. Biomedicines. 2023; 11(5):1290. DOI: 10.3390/biomedicines11051290Clemente-Suárez V.J., Redondo-Flórez L., Beltrán-Velasco A.I. et al. The role of adipokines in health and disease. Biomedicines. 2023; 11(5):1290. DOI: 10.3390/biomedicines11051290Fadhil Jaafar A., Afrisham R., Fadaei R. et al. CCN3/NOV serum levels in coronary artery disease (CAD) patients and its correlation with TNF-α and IL-6. BMC Res. Notes. 2023;16(1):306. DOI: 10.1186/s13104-02306590-xFadhil Jaafar A., Afrisham R., Fadaei R. et al. CCN3/NOV serum levels in coronary artery disease (CAD) patients and its correlation with TNF-α and IL-6. BMC Res. Notes. 2023;16(1):306. DOI: 10.1186/s13104-02306590-xGarbuzova Striukova E.V., Shramko V.S., Kashtanova E.V. et al. Adipokinecytokine profile in patients with unstable atherosclerotic plaques and abdominal obesity. Int. J. Mol. Sci. 2023;24(10):8937. DOI: 10.3390/ijms24108937Garbuzova Striukova E.V., Shramko V.S., Kashtanova E.V. et al. Adipokinecytokine profile in patients with unstable atherosclerotic plaques and abdominal obesity. Int. J. Mol. Sci. 2023;24(10):8937. DOI: 10.3390/ijms24108937Ali S., Alam R., Ahsan H., Khan S. Role of adipokines (omentin and visfatin) in coronary artery disease. Nutr. Metab. Cardiovasc. Dis. 2023;33(3):483–493. DOI: 10.1016/j.numecd.2022.11.023Ali S., Alam R., Ahsan H., Khan S. Role of adipokines (omentin and visfatin) in coronary artery disease. Nutr. Metab. Cardiovasc. Dis. 2023;33(3):483–493. DOI: 10.1016/j.numecd.2022.11.023Sasso F.C., Pafundi P.C., Marfella R. et al. Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance: the prospective AIRE Study. Cardiovasc. Diabetol. 2019;18:1–13. DOI: 10.1186/s12933-019-0826-0Sasso F.C., Pafundi P.C., Marfella R. et al. Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance: the prospective AIRE Study. Cardiovasc. Diabetol. 2019;18:1–13. DOI: 10.1186/s12933-019-0826-0Shioji K., Moriwaki S., Takeuchi Y. et al. Relationship of serum adiponectin level to adverse cardiovascular events in patients who undergo percutaneous coronary intervention. Circ. J. 2007;71(5): 675–680. DOI: 10.1253/circj.71.675Shioji K., Moriwaki S., Takeuchi Y. et al. Relationship of serum adiponectin level to adverse cardiovascular events in patients who undergo percutaneous coronary intervention. Circ. J. 2007;71(5): 675–680. DOI: 10.1253/circj.71.675Askin L., Duman H., Ozyıldız A. et al. Association between omentin-1 and coronary artery disease: pathogenesis and clinical research. Curr. Cardiol. Rev. 2020;16(3):198–201. DOI: 10.2174/1573403X16666200511085304Askin L., Duman H., Ozyıldız A. et al. Association between omentin-1 and coronary artery disease: pathogenesis and clinical research. Curr. Cardiol. Rev. 2020;16(3):198–201. DOI: 10.2174/1573403X16666200511085304Christodoulatos G.S., Antonakos G., Karampela I. et al. Circulating omentin-1 as a biomarker at the intersection of postmenopausal breast cancer occurrence and cardiometabolic risk: an observational cross-sectional study. Biomolecules. 2021;11(11):1609. DOI: 10.3390/biom11111609Christodoulatos G.S., Antonakos G., Karampela I. et al. Circulating omentin-1 as a biomarker at the intersection of postmenopausal breast cancer occurrence and cardiometabolic risk: an observational cross-sectional study. Biomolecules. 2021;11(11):1609. DOI: 10.3390/biom11111609Zhou Y., Zhang B., Hao C. et al. Omentin-A novel adipokine in respiratory diseases. Int. J. Mol. Sci. 2017;19(1):73. DOI: 10.3390/ijms19010073Zhou Y., Zhang B., Hao C. et al. Omentin-A novel adipokine in respiratory diseases. Int. J. Mol. Sci. 2017;19(1):73. DOI: 10.3390/ijms19010073Karabulut S., Afsar C.U., Karabulut M. et al. Clinical significance of serum omentin-1 levels in patients with pancreatic adenocarcinoma. BBA Clin. 2016;6:138–142. DOI: 10.1016/j.bbacli.2016.10.002Karabulut S., Afsar C.U., Karabulut M. et al. Clinical significance of serum omentin-1 levels in patients with pancreatic adenocarcinoma. BBA Clin. 2016;6:138–142. DOI: 10.1016/j.bbacli.2016.10.002Kadoglou N.P.E., Lambadiari V., Gastounioti A. et al. The relationship of novel adipokines, RBP4 and omentin-1, with carotid atherosclerosis severity and vulnerability. Atherosclerosis. 2014;235(2):606–612. DOI: 10.1016/j.atherosclerosis.2014.05.957Kadoglou N.P.E., Lambadiari V., Gastounioti A. et al. The relationship of novel adipokines, RBP4 and omentin-1, with carotid atherosclerosis severity and vulnerability. Atherosclerosis. 2014;235(2):606–612. DOI: 10.1016/j.atherosclerosis.2014.05.957Dec P., Poniewierska-Baran A., Modrzejewski A., Pawlik A. The role of omentin-1 in cancers development and progression. Cancers. 2023;15(15):3797. DOI: 10.3390/cancers15153797Dec P., Poniewierska-Baran A., Modrzejewski A., Pawlik A. The role of omentin-1 in cancers development and progression. Cancers. 2023;15(15):3797. DOI: 10.3390/cancers15153797Martínez-García M.A., Montes-Nieto R., Fernández-Durán E. et al. Evidence for masculinization of adipokine gene expression in visceral and subcutaneous adipose tissue of obese women with polycystic ovary syndrome (PCOS). J. Clin. Endocrinol. Metab. 2013;98(2):E388–E396. DOI: 10.1210/jc.2012-3414Martínez-García M.A., Montes-Nieto R., Fernández-Durán E. et al. Evidence for masculinization of adipokine gene expression in visceral and subcutaneous adipose tissue of obese women with polycystic ovary syndrome (PCOS). J. Clin. Endocrinol. Metab. 2013;98(2):E388–E396. DOI: 10.1210/jc.2012-3414Martínez-García M.Á., Moncayo S., Insenser M. еt al. Metabolic cytokines at fasting and during macronutrient challenges: influence of obesity, female androgen excess and sex. Nutrients. 2019;11(11):2566. DOI: 10.3390/nu11112566Martínez-García M.Á., Moncayo S., Insenser M. еt al. Metabolic cytokines at fasting and during macronutrient challenges: influence of obesity, female androgen excess and sex. Nutrients. 2019;11(11):2566. DOI: 10.3390/nu11112566Feijóo-Bandín S., Aragón-Herrera A., Moraña-Fernández S. et al. Adipokines and inflammation: focus on cardiovascular diseases. Int. J. Mol. Sci. 2020;21(20):7711. DOI: 10.3390/ijms21207711Feijóo-Bandín S., Aragón-Herrera A., Moraña-Fernández S. et al. Adipokines and inflammation: focus on cardiovascular diseases. Int. J. Mol. Sci. 2020;21(20):7711. DOI: 10.3390/ijms21207711Sena C.M. Omentin: a key player in glucose homeostasis, atheroprotection, and anti-inflammatory potential for cardiovascular health in obesity and diabetes. Biomedicines. 2024;12(2):284. DOI: 10.3390/biomedicines12020284Sena C.M. Omentin: a key player in glucose homeostasis, atheroprotection, and anti-inflammatory potential for cardiovascular health in obesity and diabetes. Biomedicines. 2024;12(2):284. DOI: 10.3390/biomedicines12020284Wu S.S., Liang Q.H., Liu Y. еt al. Omentin-1 stimulates human osteoblast proliferation through PI3K/Akt signal pathway. Int. J. Endocrinol. 2013;2013:368970. DOI: 10.1155/2013/368970Wu S.S., Liang Q.H., Liu Y. еt al. Omentin-1 stimulates human osteoblast proliferation through PI3K/Akt signal pathway. Int. J. Endocrinol. 2013;2013:368970. DOI: 10.1155/2013/368970Lin S., Li X., Zhang J., Zhang Y. Omentin-1: protective impact on ischemic stroke via ameliorating atherosclerosis. Clin. Chim. Acta. 2021;517: 31–40. DOI: 10.1016/j.cca.2021.02.004Lin S., Li X., Zhang J., Zhang Y. Omentin-1: protective impact on ischemic stroke via ameliorating atherosclerosis. Clin. Chim. Acta. 2021;517: 31–40. DOI: 10.1016/j.cca.2021.02.004Bai P., Abdullah F., Lodi M. et al. Association between coronary artery disease and plasma Omentin-1 levels. Cureus. 2021;13(8):e17347. DOI: 10.7759/cureus.17347Bai P., Abdullah F., Lodi M. et al. Association between coronary artery disease and plasma Omentin-1 levels. Cureus. 2021;13(8):e17347. DOI: 10.7759/cureus.17347Miroshnikova V.V., Polyakova E.A., Pobozheva I.A. еt al. FABP4 and omentin-1 gene expression in epicardial adipose tissue from coronary artery disease patients. Genet. Mol. Biol. 2021;44(4):e20200441. DOI: 10.1590/1678-4685-GMB-2020-0441Miroshnikova V.V., Polyakova E.A., Pobozheva I.A. еt al. FABP4 and omentin-1 gene expression in epicardial adipose tissue from coronary artery disease patients. Genet. Mol. Biol. 2021;44(4):e20200441. DOI: 10.1590/1678-4685-GMB-2020-0441Recinella L., Orlando G., Ferrante C. et al. Adipokines: new potential therapeutic target for obesity and metabolic, rheumatic, and cardiovascular diseases. Front. Physiol. 2020;11:578966. DOI: 10.3389/fphys.2020.578966Recinella L., Orlando G., Ferrante C. et al. Adipokines: new potential therapeutic target for obesity and metabolic, rheumatic, and cardiovascular diseases. Front. Physiol. 2020;11:578966. DOI: 10.3389/fphys.2020.578966Zhou J.P., Tong X.Y., Zhu L.P. еt al. Plasma Omentin-1 level as a predictor of good coronary collateral circulation. J. Atheroscler. Thromb. 2017;24(9):940–948. DOI: 10.5551/jat.37440Zhou J.P., Tong X.Y., Zhu L.P. еt al. Plasma Omentin-1 level as a predictor of good coronary collateral circulation. J. Atheroscler. Thromb. 2017;24(9):940–948. DOI: 10.5551/jat.37440Bolignano D., Dounousi E., Presta P. et al. Circulating Omentin-1 levels and altered iron balance in chronic haemodialysis patients. Clin. Kidney J. 2022;15(2):303–310. DOI: 10.1093/ckj/sfab189Bolignano D., Dounousi E., Presta P. et al. Circulating Omentin-1 levels and altered iron balance in chronic haemodialysis patients. Clin. Kidney J. 2022;15(2):303–310. DOI: 10.1093/ckj/sfab189Onat A., Ademoglu E., Karadeniz Y. et al. Population-based serum omentin-1 levels: paradoxical association with cardiometabolic disorders primarily in men. Biomark. Med. 2018;12(2):141–149. DOI: 10.2217/bmm-2017-0197Onat A., Ademoglu E., Karadeniz Y. et al. Population-based serum omentin-1 levels: paradoxical association with cardiometabolic disorders primarily in men. Biomark. Med. 2018;12(2):141–149. DOI: 10.2217/bmm-2017-0197Saely C.H., Leiherer A., Muendlein A. et al. Coronary patients with high plasma omentin are at a higher cardiovascular risk. Data Brief. 2015;6:158–161. DOI: 10.1016/j.dib.2015.11.065Saely C.H., Leiherer A., Muendlein A. et al. Coronary patients with high plasma omentin are at a higher cardiovascular risk. Data Brief. 2015;6:158–161. DOI: 10.1016/j.dib.2015.11.065Ozkan B., Ndumele C.E. Exploring the mechanistic link between obesity and heart failure. Curr. Diabetes Rep. 2023;23(12): 347–360. DOI: 10.1007/s11892-023-01526-yOzkan B., Ndumele C.E. Exploring the mechanistic link between obesity and heart failure. Curr. Diabetes Rep. 2023;23(12): 347–360. DOI: 10.1007/s11892-023-01526-yBaig M., Alghalayini K.W., Gazzaz Z.J., Atta H. Association of serum Omentin-1, Chemerin, and Leptin with acute myocardial infarction and its risk factors. Pak. J. Med. Sci. 2020;36(6):1183–1188. DOI: 10.12669/pjms.36.6.2372Baig M., Alghalayini K.W., Gazzaz Z.J., Atta H. Association of serum Omentin-1, Chemerin, and Leptin with acute myocardial infarction and its risk factors. Pak. J. Med. Sci. 2020;36(6):1183–1188. DOI: 10.12669/pjms.36.6.2372Zhu Y., Hu C., Du Y. et al. Time-dependent change in Omentin-1 level correlated with early improvement of myocardial function in patients with first anterior ST-segment elevation myocardial infarction after primary percutaneous coronary intervention. J. Atheroscler. Thromb. 2019;26(10):856–867. DOI: 10.5551/jat.47043Zhu Y., Hu C., Du Y. et al. Time-dependent change in Omentin-1 level correlated with early improvement of myocardial function in patients with first anterior ST-segment elevation myocardial infarction after primary percutaneous coronary intervention. J. Atheroscler. Thromb. 2019;26(10):856–867. DOI: 10.5551/jat.47043Luo J., He Z., Li Q. et al. Adipokines in atherosclerosis: unraveling complex roles. Front. Cardiovasc. Med. 2023;10:1235953. DOI: 10.3389/fcvm.2023.1235953Luo J., He Z., Li Q. et al. Adipokines in atherosclerosis: unraveling complex roles. Front. Cardiovasc. Med. 2023;10:1235953. DOI: 10.3389/fcvm.2023.1235953Кравчун П.П., Кадыкова О.И. Значение гормонов жировой ткани в патогенезе сахарного диабета 2 типа у пациентов с постинфарктным кардиосклерозом. Лечебное дело: научно-практический терапевтический журнал. 2015;(1):39–43.Kravchun P.P., Kadykova O.I. The importance of adipose tissue hormones in the pathogenesis of type 2 diabetes mellitus in patients with post-infarction cardiosclerosis. Lechebnoye delo: nauchno-prakticheskiy terapevticheskiy zhurnal. 2015;(1):39–43. (in Russian).Matloch Z., Kratochvílová H., Cinkajzlová A. et al. Changes in omentin levels and its mRNA expression in epicardial adipose tissue in patients undergoing elective cardiac surgery: the influence of type 2 diabetes and coronary heart disease. Physiol. Res. 2018;67(6): 881–890. DOI: 10.33549/physiolres.933909Matloch Z., Kratochvílová H., Cinkajzlová A. et al. Changes in omentin levels and its mRNA expression in epicardial adipose tissue in patients undergoing elective cardiac surgery: the influence of type 2 diabetes and coronary heart disease. Physiol. Res. 2018;67(6): 881–890. DOI: 10.33549/physiolres.933909Jha C.K., Mir R., Elfaki I. et al. Evaluation of the association of Omentin 1 rs2274907 A>T and rs2274908 G>A gene polymorphisms with coronary artery disease in indian population: a case control study. J. Personal. Med. 2019;9(2):30. DOI: 10.3390/jpm9020030Jha C.K., Mir R., Elfaki I. et al. Evaluation of the association of Omentin 1 rs2274907 A>T and rs2274908 G>A gene polymorphisms with coronary artery disease in indian population: a case control study. J. Personal. Med. 2019;9(2):30. DOI: 10.3390/jpm9020030Jha C.K., Mir R., Elfaki I. et al. Reply to comment: evaluation of the association of Omentin 1 rs2274907 A>T and rs2274908 G>A gene polymorphisms with coronary artery disease in indian population: a case–control study. J. Pers. Med. 2020;10(4):194. DOI: 10.3390/jpm10040194Jha C.K., Mir R., Elfaki I. et al. Reply to comment: evaluation of the association of Omentin 1 rs2274907 A>T and rs2274908 G>A gene polymorphisms with coronary artery disease in indian population: a case–control study. J. Pers. Med. 2020;10(4):194. DOI: 10.3390/jpm10040194Güçlü-Geyik F., Erkan A.F., Özuynuk A.S. et al. Val109Asp polymorphism in Intelectin 1 gene is associated with coronary artery disease severity in women. Turk. Kardiyol. Dern. Ars. 2022;50(1):34–45. DOI: 10.5543/tkda.2022.21003Güçlü-Geyik F., Erkan A.F., Özuynuk A.S. et al. Val109Asp polymorphism in Intelectin 1 gene is associated with coronary artery disease severity in women. Turk. Kardiyol. Dern. Ars. 2022;50(1):34–45. DOI: 10.5543/tkda.2022.21003Исакова Ж.Т., Кипень В.Н., Айтбаев К.А. и др. Ассоциация полиморфных вариантов неаллельных генов ADIPOQ, MTHFR, PON1, KCNJ11, TCF7L2, ITLN1 и PPARG с клинико-лабораторными показателями среди пациентов с ожирением в Кыргызской республике. Молекулярная медицина. 2022;20(5):42–52. Isakova J.T., Kipen V.N., Aitbaev K.A. et al. Association of polymorphic variants of non-allelic genes ADIPOQ, MTHFR, PON1, KCNJ11, TCF7L2, ITLN1 and PPARG with clinical and laboratory parameters among obese patients from Kyrgyz Republic. Molecular medicine. 2022;20(5): 42–52. (in Russian). DOI: 10.29296/24999490-2022-05-06Isakova J.T., Kipen V.N., Aitbaev K.A. et al. Association of polymorphic variants of non-allelic genes ADIPOQ, MTHFR, PON1, KCNJ11, TCF7L2, ITLN1 and PPARG with clinical and laboratory parameters among obese patients from Kyrgyz Republic. Molecular medicine. 2022;20(5): 42–52. (in Russian). DOI: 10.29296/24999490-2022-05-06Du Y., Ji Q., Cai L. et al. Association between omentin-1 expression in human epicardial adipose tissue and coronary atherosclerosis. Cardiovasc. Diabetol. 2016;15:90. DOI: 10.1186/s12933-016-0406-5Du Y., Ji Q., Cai L. et al. Association between omentin-1 expression in human epicardial adipose tissue and coronary atherosclerosis. Cardiovasc. Diabetol. 2016;15:90. DOI: 10.1186/s12933-016-0406-5Klein C., Ninni S., Coisne A. et al. Omentin-1, epicardial fat and coronary artery disease. Atherosclerosis. 2016;255:224–225. DOI: 10.1016/j.atherosclerosis.2016.10.021Klein C., Ninni S., Coisne A. et al. Omentin-1, epicardial fat and coronary artery disease. Atherosclerosis. 2016;255:224–225. DOI: 10.1016/j.atherosclerosis.2016.10.021Fernández-Trasancos Á., Agra R.M., García-Acuña J.M. et al. Omentin treatment of epicardial fat improves its anti-inflammatory activity and paracrine benefit on smooth muscle cells. Obesity (Silver Spring). 2017;25(6):1042–1049. DOI: 10.1002/oby.21832Fernández-Trasancos Á., Agra R.M., García-Acuña J.M. et al. Omentin treatment of epicardial fat improves its anti-inflammatory activity and paracrine benefit on smooth muscle cells. Obesity (Silver Spring). 2017;25(6):1042–1049. DOI: 10.1002/oby.21832Saddic L.A., Nicoloro S.M., Gupta O.T. et al. Joint analysis of left ventricular expression and circulating plasma levels of Omentin after myocardial ischemia. Cardiovasc. Diabetol. 2017;16(1):87. DOI: 10.1186/s12933-017-0567-xSaddic L.A., Nicoloro S.M., Gupta O.T. et al. Joint analysis of left ventricular expression and circulating plasma levels of Omentin after myocardial ischemia. Cardiovasc. Diabetol. 2017;16(1):87. DOI: 10.1186/s12933-017-0567-xPahwa R., Singh A., Adams-Huet B. et al. Increased inflammasome activity in subcutaneous adipose tissue of patients with metabolic syndrome. Diabetes Metab. Res. Rev. 2021;37(3):e3383. DOI: 10.1002/dmrr.3383Pahwa R., Singh A., Adams-Huet B. et al. Increased inflammasome activity in subcutaneous adipose tissue of patients with metabolic syndrome. Diabetes Metab. Res. Rev. 2021;37(3):e3383. DOI: 10.1002/dmrr.3383Kadoglou N.P.E., Kassimis G., Patsourakos N. et al. Omentin-1 and vaspin serum levels in patients with pre-clinical carotid atherosclerosis and the effect of statin therapy on them. Cytokine. 2021;138:155364. DOI: 10.1016/j.cyto.2020.155364Kadoglou N.P.E., Kassimis G., Patsourakos N. et al. Omentin-1 and vaspin serum levels in patients with pre-clinical carotid atherosclerosis and the effect of statin therapy on them. Cytokine. 2021;138:155364. DOI: 10.1016/j.cyto.2020.155364Kadoglou N.P.E., Velidakis N., Khattab E. et al. The interplay between statins and adipokines. Is this another explanation of statins’ ‘pleiotropic’effects? Cytokine. 2021;148:155698. DOI: 10.1016/j.cyto.2021.155698Kadoglou N.P.E., Velidakis N., Khattab E. et al. The interplay between statins and adipokines. Is this another explanation of statins’ ‘pleiotropic’effects? Cytokine. 2021;148:155698. DOI: 10.1016/j.cyto.2021.155698Jung H.N., Jung C.H. The role of anti-inflammatory adipokines in cardiometabolic disorders: moving beyond adiponectin. International Journal of Molecular Sciences. 2021;22(24):13529. DOI: 10.3390/ijms222413529Jung H.N., Jung C.H. The role of anti-inflammatory adipokines in cardiometabolic disorders: moving beyond adiponectin. International Journal of Molecular Sciences. 2021;22(24):13529. DOI: 10.3390/ijms222413529

The authors declare that there are no conflicts of interest present.